English
简体中文
Total: £ 56.28
Published Date: 2025-12-03 | Pages: 134 | Tables: 135 | Medical Care
The global market for Pharmaceutical Biomanufacturing was valued at US$ 518560 million in the year 2024 and is projected to reach a revised size of US$ 951994 million by 2031, growing at a CAGR of 9.4% during the forecast period.
In the pharmaceutical field, biomanufacturing refers to the use of living biological systems (such as mammalian, microbial, or plant cells) as "production factories" to transform complex biomolecules into drugs for the treatment or prevention of diseases through precisely controlled cultivation, fermentation, separation, and purification processes. This process differs from traditional chemical synthesis in that it emphasizes the correct folding, modification, and biological activity of macromolecules such as proteins and nucleic acids. It also requires strict adherence to regulatory standards such as cGMP to ensure product safety, efficacy, and batch consistency. Typical products include monoclonal antibodies, recombinant proteins, vaccines, and gene or cell therapy formulations, reflecting the shift in modern pharmaceutical manufacturing from chemical manufacturing to bio-driven innovation.
The upstream biomanufacturing process in pharmaceuticals encompasses key supply chains such as equipment, reagents, and raw and excipient materials, forming the foundation of the entire industry chain. Equipment includes cell separation and elutriation machines, flow cytometers, cell culture incubators, biosafety cabinets, reactors (such as Wave, G-Rex, and CliniMACS Prodigy), nucleic acid synthesizers, HPLC separation systems, and fermenters. These equipment are widely used in the production of CAR-T, small nucleic acids, mRNA, monoclonal antibodies, and vaccines. Raw materials include DNA plasmids, enzymes, lipid nanoparticles, culture media, cell lines (such as CHO), cytokines, and chromatography media. The upstream industry landscape is still dominated by multinational giants such as GE Healthcare, Lonza, Miltenyi, Thermo Fisher, Cytiva, and Sartorius. Domestic companies such as LePure Biopharmaceuticals, Novozymes, GenScript, Nanovitamin Biotech, Lanxiao Technology, Dongfulong, and Chutian Technology are gradually replacing imports, particularly with breakthroughs in separation and purification media, as well as certain reagents and equipment. However, overall, gaps remain in high-end instruments and core consumables. Overall, the upstream industry demonstrates a pattern of "high technological barriers for multinational companies and rapid catching-up for local companies."
The midstream sector primarily focuses on the R&D and production of biopharmaceuticals, including antibody drugs, CAR-T therapies, mRNA vaccines, small nucleic acid drugs, recombinant proteins, and blood products. This sector encompasses both large pharmaceutical companies and CDMO/CMO service providers. Globally, multinational pharmaceutical companies such as Roche, Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb still dominate high-end innovation in the industry. In China, leading domestic companies such as WuXi AppTec, Corning Life Sciences, GenScript, Asymchem, Zhifei Biopharmaceuticals, Sinovac Biotech, and Kangtai Biologics are experiencing rapid growth, with some achieving international breakthroughs in vaccines, CDMOs, and antibody drugs. Geographically, North America and Europe are centers of innovation and R&D, while the Asia-Pacific region, particularly China, has gradually become a global hub for biomanufacturing production, creating a "European and American innovation, Asia-Pacific manufacturing" landscape. The midstream sector is currently transitioning towards digital factories, continuous flow production, and modularized capacity layouts, giving Chinese companies greater opportunities to directly adopt next-generation process standards when building new production capacity.
The downstream biomanufacturing sector in the pharmaceutical industry primarily serves healthcare providers and patients. Typical users include large tertiary hospitals, specialized oncology centers, gene and cell therapy research institutions, and hematology hospitals, all of which are equipped to implement complex therapies such as CAR-T and gene therapy. For vaccines and conventional biopharmaceuticals, sales channels primarily rely on centralized government procurement, the medical insurance payment system, cold chain logistics, and commercial distribution. For example, domestic vaccines are distributed on a large scale through CDCs and vaccination sites, while blood products and monoclonal antibodies are distributed through hospital pharmacies, direct supply from pharmaceutical companies, and specialized distributors. With policy initiatives and evolving payment methods, volume-based procurement and medical insurance access have become key factors influencing the size of the downstream market. Furthermore, cold chain logistics (such as those provided by CIMC and Haier BioMedical) and third-party drug distribution (such as Jointown) play an indispensable role in ensuring transportation safety and efficiency. It can be said that the downstream sector is both the endpoint for biomanufacturing value realization and the core driver of market expansion and widespread adoption.
The upstream process for antibody drugs centers on cell culture and purification processes. Their production relies on key raw materials such as high-quality cell culture media, enzyme tools, and CHO cell lines. Furthermore, pipettes, chromatography media, and disposable consumables are crucial for process stability. Regarding equipment, large-scale stirred tanks and airlift tanks are the mainstream culture methods, coupled with separation and purification systems to ensure antibody product quality. In terms of supply, international manufacturers such as Thermo Fisher Scientific, Roche, and Illumina maintain their dominant position, while domestic companies such as LePure Biopharmaceuticals, Novozymes, and GenScript are gradually achieving breakthroughs in culture media, cell lines, and some consumables, driving import substitution.
The production process of recombinant protein drugs relies on genetically engineered vectors and host cell expression systems. The upstream process includes gene vector construction, cell culture, protein extraction, and chromatography purification. CHO cells remain the industry's mainstream host, and large-scale production is achieved through the integration of reactors, quality control instruments, and high-performance chromatography media. In the international market, giants such as Sartorius, Danaher (Cytiva), and GE Healthcare control high-end equipment and purification processes, while Chinese companies such as OptoMed, Sino Biological, and Labtech are gradually becoming competitive in some equipment and reagents. Overall, this sector demonstrates continued reliance on multinational companies, while domestic companies are rapidly catching up through technological accumulation.
The upstream process of blood products relies on the collection, separation, and purification of healthy human plasma, making apheresis centers the only legal source of raw materials. In terms of technology, traditional low-temperature ethanol separation processes are still widely used, but they lack purity and efficiency. Therefore, column chromatography and ultrafiltration technologies are gradually being introduced to improve protein yield and product safety. Upstream equipment includes plasma separation equipment, chromatography systems, and filtration consumables, with key suppliers primarily concentrated in the European and American markets. While domestic companies such as Hualan Biotechnology, Tiantan Biotechnology, and Shanghai RAAS have advantages in plasma collection and certain process technologies, they still rely on imports for high-end chromatography media and equipment.
The upstream component of vaccines is relatively complex, encompassing a variety of raw materials such as culture media, antibiotics, enzyme tools, liposomes, drug delivery vehicles, reagents, and packaging materials. At the equipment level, fermenters, reactors, separation and purification systems, and quality control instruments are essential core components. The global market is dominated by multinational giants such as Thermo Fisher Scientific, Danaher, and Sartorius, whose products are highly competitive in terms of quality and GMP standards. Chinese companies such as LePure Biotechnology, Novozymes, Dongfulong, Chutian Technology, and Jiankai Technology have gradually established scale in culture media, certain equipment, and purification consumables, demonstrating strong industrial responsiveness, particularly within the COVID-19 vaccine supply chain. The upstream process of CAR-T cell therapy relies on high-end equipment and key reagents. The production process relies on equipment such as flow cytometers, blood cell separation and elutriation machines, cell culture incubators, and biosafety cabinets. It also requires consumables such as magnetic bead enrichment columns, electroporators, and T-flasks, culture bags, and Wave reactors. Cytokines and transfection reagents are key ingredients for ensuring cell viability and the success rate of gene delivery. Currently, international companies such as GE Healthcare, Miltenyi, Lonza, and Thermo Fisher Scientific hold a commanding position in this field. While domestic companies offer some competitiveness in consumables pricing, their overall quality lags behind international standards, leading local R&D companies to rely more heavily on imported products.
The upstream process of small nucleic acid drugs primarily focuses on synthesis and purification. Core equipment includes solid-phase nucleic acid synthesizers and reversed-phase HPLC separation systems, combined with high-purity nucleotide monomers and reagents to complete the synthesis process. The international market is dominated by companies such as Cytiva (a Danaher subsidiary) and Thermo Fisher Scientific, which have established technological barriers to GMP-grade equipment and key consumables. In China, Nanotech, Lanxiao Technology, and Boglon are gradually replacing domestically produced materials in separation and purification fillers, driving down production costs. However, they still rely on imports for industrial synthesis equipment. As the industry scales up, breakthroughs in the domestic supply chain are seen as key to reducing costs and improving domestic controllability.
In recent years, the pharmaceutical industry's R&D focus has shifted from solely focusing on the discovery and optimization of small molecule drugs. Driven by biomanufacturing, the product portfolio has evolved into a multimodal, biology-centric landscape. While traditional proteins and monoclonal antibodies remain the bulk of the market, manufacturing processes are constantly being optimized to improve yield and quality consistency. Meanwhile, emerging therapeutic modalities such as cell and gene therapies, mRNA, nucleic acid therapies, and gene editing-related products are placing new demands on biomanufacturing. Upstream cell line development, expression system optimization, vector production, sterile and pyrogen-free downstream purification, and process stability for both in vitro and in vivo delivery systems have all become key R&D priorities. Consequently, the boundaries between R&D and manufacturing are becoming increasingly blurred: early-stage molecular design must consider manufacturability for scalable production, while process development, in turn, influences clinical dosing regimens and development cadence. With the maturity of AI/data-driven design, synthetic biology, and high-throughput screening technologies, the path from early target identification to producible biologics has been significantly shortened. This, in turn, requires manufacturing teams to engage earlier in early drug development to ensure that candidate molecules do not encounter unresolvable process bottlenecks when entering mid- to late-stage large-scale production. As a result, R&D trends are showing a significant shift from single-molecule innovation to molecule-process co-design. This trend will continue to intensify, driving companies to adjust their R&D organizational structures and investment allocations to balance scientific innovation with production feasibility.
The technological evolution of biomanufacturing is undergoing a transition from traditional batch processes to continuous production and intelligent manufacturing. Continuous bioreactors, real-time release testing (RTRT), online process analytical technology (PAT), and closed-loop automation systems can significantly improve unit capacity utilization, shorten release times, and reduce human errors, while also enabling rapid scale-up and flexible capacity adjustments. Digitalization (including production-level data platforms, AI-driven process optimization, and predictive maintenance) enables faster development of relationships between process parameters and quality attributes, accelerating improvements in batch yields. Regarding platformization, product lines such as monoclonal antibodies (mAbs) and viral vectors are increasingly adopting standardized platform processes: reusable expression systems, universal downstream purification columns, and modular facilities (such as mobile or "factory-as-a-module") to reduce the cost and time required to introduce new products. Green manufacturing and low-carbon processes are also gradually being incorporated into the technology pipeline, such as reducing solvent use and improving resource recycling. Overall, these technologies are characterized by high automation, strong data reliance, and platform-based reuse. This places higher demands on companies' R&D organizations, technical reserves, and capital investment, while also providing companies with advanced processes with a lasting competitive advantage.
The biomanufacturing sector is characterized by significant scale and technology concentration. Global large pharmaceutical companies and leading CDMOs/CMOs dominate high-end production capacity and complex process capabilities. At the same time, a large number of specialized small and medium-sized enterprises, contract research and production organizations, and technical service providers have emerged in the market, forming a complex network of collaborations. Large innovative pharmaceutical companies, driven by flexibility and cost considerations, are increasingly outsourcing some manufacturing to third-party CDMOs with scale and regulatory compliance, allowing them to focus their resources on core R&D and commercialization. In turn, CDMOs are rapidly increasing their bargaining power within the supply chain by investing in serialization, expanding sterile biologics production capacity, and acquiring key process patents through mergers and acquisitions. Furthermore, cross-border collaborations, licensing, co-development, and joint ventures are becoming common strategies for rapidly entering new markets or securing regional regulatory compliance pathways. It's worth noting that collaboration doesn't necessarily mean weakening competition: Building on platformization and standardization, companies are creating competitive barriers through differentiated services, patent portfolios, quality systems, and delivery capabilities. In short, the industry's key characteristics include a strong platform effect, a refined division of labor, and regularized collaboration. Within this ecosystem, there's both concentrated competition among large-scale companies and the rapid growth of small and medium-sized players relying on specialized capabilities.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Biomanufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Biomanufacturing.
The Pharmaceutical Biomanufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical Biomanufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, by Class and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical Biomanufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
Novo Nordisk
Sanofi
Johnson & Johnson
AbbVie
Amgen
AstraZeneca
Takeda Pharmaceuticals
Bristol-Myers Squib
Pfizer
Eli Lilly
Novartis
GSK
CSL Limited
Regeneron Pharmaceuticals
Gilford
Biogen
GileadSciences
Moderna
Sarepta Therapeutics, Inc.
Changchun High-Tech Industry
Sino Biopharmaceutical Limited
Sobi
3SBio Inc.
Beijing Tiantan Biological
Innovent Biologics
Qilu Pharmaceutical
Boehringer Ingelheim
BeiGene
Jiangsu Hengrui Pharmaceuticals
Hualan Biological
Shanghai Henlius Biotech
Taibang Biologic
Gan & Lee Pharmaceuticals
Anhui Anke Biotechnology
Tonghua Dongbao Pharmaceutical
Shanghai Junshi Biosciences
Sichuan Yuanda Shuyang Pharmaceutical
Kexing Biopharm
Shanghai RAAS Blood Products
Chongqing Zhifei Biological Products
Beijing WANTAI Biological
Bio-Thera Solutions
Ionis Pharmaceuticals
Alphamab Oncology
CARsgen
Segment by Type
Antibody Drugs
Recombinant Protein Drugs
Blood Products
Vaccine Preparations
CAR-T Drugs
Small Nucleic Acid Drugs
Others
Segment by Class
Monoclonal Antibodies
Antibody-drug Conjugates (ADCs)
Peptide Drugs
Enzyme Replacement Therapy
Human Albumin
Immunoglobulins
Coagulation Factors
COVID-19 Vaccines
Other Vaccines
CAR-T Drugs
Small Nucleic Acid Drugs
Others
Segment by Application
Oncology
Infectious Diseases
Immune and Inflammatory Diseases
Endocrine and Metabolic Diseases
Neurological Diseases
Hematologic Diseases
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Class etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical Biomanufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody Drugs
1.2.3 Recombinant Protein Drugs
1.2.4 Blood Products
1.2.5 Vaccine Preparations
1.2.6 CAR-T Drugs
1.2.7 Small Nucleic Acid Drugs
1.2.8 Others
1.3 Market by Class
1.3.1 Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Class: 2020 VS 2024 VS 2031
1.3.2 Monoclonal Antibodies
1.3.3 Antibody-drug Conjugates (ADCs)
1.3.4 Peptide Drugs
1.3.5 Enzyme Replacement Therapy
1.3.6 Human Albumin
1.3.7 Immunoglobulins
1.3.8 Coagulation Factors
1.3.9 COVID-19 Vaccines
1.3.10 Other Vaccines
1.4 Market by Application
1.4.1 Global Pharmaceutical Biomanufacturing Market Growth by Application: 2020 VS 2024 VS 2031
1.4.2 Oncology
1.4.3 Infectious Diseases
1.4.4 Immune and Inflammatory Diseases
1.4.5 Endocrine and Metabolic Diseases
1.4.6 Neurological Diseases
1.4.7 Hematologic Diseases
1.4.8 Others
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical Biomanufacturing Market Perspective (2020-2031)
2.2 Global Pharmaceutical Biomanufacturing Growth Trends by Region
2.2.1 Global Pharmaceutical Biomanufacturing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharmaceutical Biomanufacturing Historic Market Size by Region (2020-2025)
2.2.3 Pharmaceutical Biomanufacturing Forecasted Market Size by Region (2026-2031)
2.3 Pharmaceutical Biomanufacturing Market Dynamics
2.3.1 Pharmaceutical Biomanufacturing Industry Trends
2.3.2 Pharmaceutical Biomanufacturing Market Drivers
2.3.3 Pharmaceutical Biomanufacturing Market Challenges
2.3.4 Pharmaceutical Biomanufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical Biomanufacturing Players by Revenue
3.1.1 Global Top Pharmaceutical Biomanufacturing Players by Revenue (2020-2025)
3.1.2 Global Pharmaceutical Biomanufacturing Revenue Market Share by Players (2020-2025)
3.2 Global Top Pharmaceutical Biomanufacturing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharmaceutical Biomanufacturing Revenue
3.4 Global Pharmaceutical Biomanufacturing Market Concentration Ratio
3.4.1 Global Pharmaceutical Biomanufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical Biomanufacturing Revenue in 2024
3.5 Global Key Players of Pharmaceutical Biomanufacturing Head office and Area Served
3.6 Global Key Players of Pharmaceutical Biomanufacturing, Product and Application
3.7 Global Key Players of Pharmaceutical Biomanufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical Biomanufacturing Breakdown Data by Type
4.1 Global Pharmaceutical Biomanufacturing Historic Market Size by Type (2020-2025)
4.2 Global Pharmaceutical Biomanufacturing Forecasted Market Size by Type (2026-2031)
5 Pharmaceutical Biomanufacturing Breakdown Data by Application
5.1 Global Pharmaceutical Biomanufacturing Historic Market Size by Application (2020-2025)
5.2 Global Pharmaceutical Biomanufacturing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical Biomanufacturing Market Size (2020-2031)
6.2 North America Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)
6.4 North America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical Biomanufacturing Market Size (2020-2031)
7.2 Europe Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)
7.4 Europe Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical Biomanufacturing Market Size (2020-2031)
8.2 Asia-Pacific Pharmaceutical Biomanufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2020-2025)
8.4 Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Pharmaceutical Biomanufacturing Market Size (2020-2031)
9.2 Latin America Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)
9.4 Latin America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical Biomanufacturing Market Size (2020-2031)
10.2 Middle East & Africa Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)
10.4 Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Pharmaceutical Biomanufacturing Introduction
11.1.4 Roche Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Pharmaceutical Biomanufacturing Introduction
11.2.4 Merck Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.2.5 Merck Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Pharmaceutical Biomanufacturing Introduction
11.3.4 Novo Nordisk Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Pharmaceutical Biomanufacturing Introduction
11.4.4 Sanofi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Pharmaceutical Biomanufacturing Introduction
11.5.4 Johnson & Johnson Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Pharmaceutical Biomanufacturing Introduction
11.6.4 AbbVie Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.6.5 AbbVie Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Pharmaceutical Biomanufacturing Introduction
11.7.4 Amgen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Pharmaceutical Biomanufacturing Introduction
11.8.4 AstraZeneca Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Takeda Pharmaceuticals
11.9.1 Takeda Pharmaceuticals Company Details
11.9.2 Takeda Pharmaceuticals Business Overview
11.9.3 Takeda Pharmaceuticals Pharmaceutical Biomanufacturing Introduction
11.9.4 Takeda Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.9.5 Takeda Pharmaceuticals Recent Development
11.10 Bristol-Myers Squib
11.10.1 Bristol-Myers Squib Company Details
11.10.2 Bristol-Myers Squib Business Overview
11.10.3 Bristol-Myers Squib Pharmaceutical Biomanufacturing Introduction
11.10.4 Bristol-Myers Squib Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.10.5 Bristol-Myers Squib Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Pharmaceutical Biomanufacturing Introduction
11.11.4 Pfizer Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.11.5 Pfizer Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Details
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Pharmaceutical Biomanufacturing Introduction
11.12.4 Eli Lilly Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.12.5 Eli Lilly Recent Development
11.13 Novartis
11.13.1 Novartis Company Details
11.13.2 Novartis Business Overview
11.13.3 Novartis Pharmaceutical Biomanufacturing Introduction
11.13.4 Novartis Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.13.5 Novartis Recent Development
11.14 GSK
11.14.1 GSK Company Details
11.14.2 GSK Business Overview
11.14.3 GSK Pharmaceutical Biomanufacturing Introduction
11.14.4 GSK Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.14.5 GSK Recent Development
11.15 CSL Limited
11.15.1 CSL Limited Company Details
11.15.2 CSL Limited Business Overview
11.15.3 CSL Limited Pharmaceutical Biomanufacturing Introduction
11.15.4 CSL Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.15.5 CSL Limited Recent Development
11.16 Regeneron Pharmaceuticals
11.16.1 Regeneron Pharmaceuticals Company Details
11.16.2 Regeneron Pharmaceuticals Business Overview
11.16.3 Regeneron Pharmaceuticals Pharmaceutical Biomanufacturing Introduction
11.16.4 Regeneron Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.16.5 Regeneron Pharmaceuticals Recent Development
11.17 Gilford
11.17.1 Gilford Company Details
11.17.2 Gilford Business Overview
11.17.3 Gilford Pharmaceutical Biomanufacturing Introduction
11.17.4 Gilford Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.17.5 Gilford Recent Development
11.18 Biogen
11.18.1 Biogen Company Details
11.18.2 Biogen Business Overview
11.18.3 Biogen Pharmaceutical Biomanufacturing Introduction
11.18.4 Biogen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.18.5 Biogen Recent Development
11.19 GileadSciences
11.19.1 GileadSciences Company Details
11.19.2 GileadSciences Business Overview
11.19.3 GileadSciences Pharmaceutical Biomanufacturing Introduction
11.19.4 GileadSciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.19.5 GileadSciences Recent Development
11.20 Moderna
11.20.1 Moderna Company Details
11.20.2 Moderna Business Overview
11.20.3 Moderna Pharmaceutical Biomanufacturing Introduction
11.20.4 Moderna Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.20.5 Moderna Recent Development
11.21 Sarepta Therapeutics, Inc.
11.21.1 Sarepta Therapeutics, Inc. Company Details
11.21.2 Sarepta Therapeutics, Inc. Business Overview
11.21.3 Sarepta Therapeutics, Inc. Pharmaceutical Biomanufacturing Introduction
11.21.4 Sarepta Therapeutics, Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.21.5 Sarepta Therapeutics, Inc. Recent Development
11.22 Changchun High-Tech Industry
11.22.1 Changchun High-Tech Industry Company Details
11.22.2 Changchun High-Tech Industry Business Overview
11.22.3 Changchun High-Tech Industry Pharmaceutical Biomanufacturing Introduction
11.22.4 Changchun High-Tech Industry Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.22.5 Changchun High-Tech Industry Recent Development
11.23 Sino Biopharmaceutical Limited
11.23.1 Sino Biopharmaceutical Limited Company Details
11.23.2 Sino Biopharmaceutical Limited Business Overview
11.23.3 Sino Biopharmaceutical Limited Pharmaceutical Biomanufacturing Introduction
11.23.4 Sino Biopharmaceutical Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.23.5 Sino Biopharmaceutical Limited Recent Development
11.24 Sobi
11.24.1 Sobi Company Details
11.24.2 Sobi Business Overview
11.24.3 Sobi Pharmaceutical Biomanufacturing Introduction
11.24.4 Sobi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.24.5 Sobi Recent Development
11.25 3SBio Inc.
11.25.1 3SBio Inc. Company Details
11.25.2 3SBio Inc. Business Overview
11.25.3 3SBio Inc. Pharmaceutical Biomanufacturing Introduction
11.25.4 3SBio Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.25.5 3SBio Inc. Recent Development
11.26 Beijing Tiantan Biological
11.26.1 Beijing Tiantan Biological Company Details
11.26.2 Beijing Tiantan Biological Business Overview
11.26.3 Beijing Tiantan Biological Pharmaceutical Biomanufacturing Introduction
11.26.4 Beijing Tiantan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.26.5 Beijing Tiantan Biological Recent Development
11.27 Innovent Biologics
11.27.1 Innovent Biologics Company Details
11.27.2 Innovent Biologics Business Overview
11.27.3 Innovent Biologics Pharmaceutical Biomanufacturing Introduction
11.27.4 Innovent Biologics Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.27.5 Innovent Biologics Recent Development
11.28 Qilu Pharmaceutical
11.28.1 Qilu Pharmaceutical Company Details
11.28.2 Qilu Pharmaceutical Business Overview
11.28.3 Qilu Pharmaceutical Pharmaceutical Biomanufacturing Introduction
11.28.4 Qilu Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.28.5 Qilu Pharmaceutical Recent Development
11.29 Boehringer Ingelheim
11.29.1 Boehringer Ingelheim Company Details
11.29.2 Boehringer Ingelheim Business Overview
11.29.3 Boehringer Ingelheim Pharmaceutical Biomanufacturing Introduction
11.29.4 Boehringer Ingelheim Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.29.5 Boehringer Ingelheim Recent Development
11.30 BeiGene
11.30.1 BeiGene Company Details
11.30.2 BeiGene Business Overview
11.30.3 BeiGene Pharmaceutical Biomanufacturing Introduction
11.30.4 BeiGene Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.30.5 BeiGene Recent Development
11.31 Jiangsu Hengrui Pharmaceuticals
11.31.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.31.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.31.3 Jiangsu Hengrui Pharmaceuticals Pharmaceutical Biomanufacturing Introduction
11.31.4 Jiangsu Hengrui Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.31.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.32 Hualan Biological
11.32.1 Hualan Biological Company Details
11.32.2 Hualan Biological Business Overview
11.32.3 Hualan Biological Pharmaceutical Biomanufacturing Introduction
11.32.4 Hualan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.32.5 Hualan Biological Recent Development
11.33 Shanghai Henlius Biotech
11.33.1 Shanghai Henlius Biotech Company Details
11.33.2 Shanghai Henlius Biotech Business Overview
11.33.3 Shanghai Henlius Biotech Pharmaceutical Biomanufacturing Introduction
11.33.4 Shanghai Henlius Biotech Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.33.5 Shanghai Henlius Biotech Recent Development
11.34 Taibang Biologic
11.34.1 Taibang Biologic Company Details
11.34.2 Taibang Biologic Business Overview
11.34.3 Taibang Biologic Pharmaceutical Biomanufacturing Introduction
11.34.4 Taibang Biologic Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.34.5 Taibang Biologic Recent Development
11.35 Gan & Lee Pharmaceuticals
11.35.1 Gan & Lee Pharmaceuticals Company Details
11.35.2 Gan & Lee Pharmaceuticals Business Overview
11.35.3 Gan & Lee Pharmaceuticals Pharmaceutical Biomanufacturing Introduction
11.35.4 Gan & Lee Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.35.5 Gan & Lee Pharmaceuticals Recent Development
11.36 Anhui Anke Biotechnology
11.36.1 Anhui Anke Biotechnology Company Details
11.36.2 Anhui Anke Biotechnology Business Overview
11.36.3 Anhui Anke Biotechnology Pharmaceutical Biomanufacturing Introduction
11.36.4 Anhui Anke Biotechnology Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.36.5 Anhui Anke Biotechnology Recent Development
11.37 Tonghua Dongbao Pharmaceutical
11.37.1 Tonghua Dongbao Pharmaceutical Company Details
11.37.2 Tonghua Dongbao Pharmaceutical Business Overview
11.37.3 Tonghua Dongbao Pharmaceutical Pharmaceutical Biomanufacturing Introduction
11.37.4 Tonghua Dongbao Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.37.5 Tonghua Dongbao Pharmaceutical Recent Development
11.38 Shanghai Junshi Biosciences
11.38.1 Shanghai Junshi Biosciences Company Details
11.38.2 Shanghai Junshi Biosciences Business Overview
11.38.3 Shanghai Junshi Biosciences Pharmaceutical Biomanufacturing Introduction
11.38.4 Shanghai Junshi Biosciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.38.5 Shanghai Junshi Biosciences Recent Development
11.39 Sichuan Yuanda Shuyang Pharmaceutical
11.39.1 Sichuan Yuanda Shuyang Pharmaceutical Company Details
11.39.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
11.39.3 Sichuan Yuanda Shuyang Pharmaceutical Pharmaceutical Biomanufacturing Introduction
11.39.4 Sichuan Yuanda Shuyang Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.39.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Development
11.40 Kexing Biopharm
11.40.1 Kexing Biopharm Company Details
11.40.2 Kexing Biopharm Business Overview
11.40.3 Kexing Biopharm Pharmaceutical Biomanufacturing Introduction
11.40.4 Kexing Biopharm Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)
11.40.5 Kexing Biopharm Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antibody Drugs
Table 3. Key Players of Recombinant Protein Drugs
Table 4. Key Players of Blood Products
Table 5. Key Players of Vaccine Preparations
Table 6. Key Players of CAR-T Drugs
Table 7. Key Players of Small Nucleic Acid Drugs
Table 8. Key Players of Others
Table 9. Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Class (US$ Million): 2020 VS 2024 VS 2031
Table 10. Key Players of Monoclonal Antibodies
Table 11. Key Players of Antibody-drug Conjugates (ADCs)
Table 12. Key Players of Peptide Drugs
Table 13. Key Players of Enzyme Replacement Therapy
Table 14. Key Players of Human Albumin
Table 15. Key Players of Immunoglobulins
Table 16. Key Players of Coagulation Factors
Table 17. Global Pharmaceutical Biomanufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 18. Global Pharmaceutical Biomanufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 19. Global Pharmaceutical Biomanufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 20. Global Pharmaceutical Biomanufacturing Market Share by Region (2020-2025)
Table 21. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 22. Global Pharmaceutical Biomanufacturing Market Share by Region (2026-2031)
Table 23. Pharmaceutical Biomanufacturing Market Trends
Table 24. Pharmaceutical Biomanufacturing Market Drivers
Table 25. Pharmaceutical Biomanufacturing Market Challenges
Table 26. Pharmaceutical Biomanufacturing Market Restraints
Table 27. Global Pharmaceutical Biomanufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 28. Global Pharmaceutical Biomanufacturing Market Share by Players (2020-2025)
Table 29. Global Top Pharmaceutical Biomanufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Biomanufacturing as of 2024)
Table 30. Ranking of Global Top Pharmaceutical Biomanufacturing Companies by Revenue (US$ Million) in 2024
Table 31. Global 5 Largest Players Market Share by Pharmaceutical Biomanufacturing Revenue (CR5 and HHI) & (2020-2025)
Table 32. Global Key Players of Pharmaceutical Biomanufacturing, Headquarters and Area Served
Table 33. Global Key Players of Pharmaceutical Biomanufacturing, Product and Application
Table 34. Global Key Players of Pharmaceutical Biomanufacturing, Date of Enter into This Industry
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Pharmaceutical Biomanufacturing Market Size by Type (2020-2025) & (US$ Million)
Table 37. Global Pharmaceutical Biomanufacturing Revenue Market Share by Type (2020-2025)
Table 38. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 39. Global Pharmaceutical Biomanufacturing Revenue Market Share by Type (2026-2031)
Table 40. Global Pharmaceutical Biomanufacturing Market Size by Application (2020-2025) & (US$ Million)
Table 41. Global Pharmaceutical Biomanufacturing Revenue Market Share by Application (2020-2025)
Table 42. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 43. Global Pharmaceutical Biomanufacturing Revenue Market Share by Application (2026-2031)
Table 44. North America Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. North America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 46. North America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 47. Europe Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Europe Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 49. Europe Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 50. Asia-Pacific Pharmaceutical Biomanufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 51. Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 52. Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2026-2031) & (US$ Million)
Table 53. Latin America Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Latin America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 55. Latin America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 56. Middle East & Africa Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 57. Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 58. Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 59. Roche Company Details
Table 60. Roche Business Overview
Table 61. Roche Pharmaceutical Biomanufacturing Product
Table 62. Roche Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 63. Roche Recent Development
Table 64. Merck Company Details
Table 65. Merck Business Overview
Table 66. Merck Pharmaceutical Biomanufacturing Product
Table 67. Merck Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 68. Merck Recent Development
Table 69. Novo Nordisk Company Details
Table 70. Novo Nordisk Business Overview
Table 71. Novo Nordisk Pharmaceutical Biomanufacturing Product
Table 72. Novo Nordisk Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 73. Novo Nordisk Recent Development
Table 74. Sanofi Company Details
Table 75. Sanofi Business Overview
Table 76. Sanofi Pharmaceutical Biomanufacturing Product
Table 77. Sanofi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 78. Sanofi Recent Development
Table 79. Johnson & Johnson Company Details
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Pharmaceutical Biomanufacturing Product
Table 82. Johnson & Johnson Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. AbbVie Company Details
Table 85. AbbVie Business Overview
Table 86. AbbVie Pharmaceutical Biomanufacturing Product
Table 87. AbbVie Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 88. AbbVie Recent Development
Table 89. Amgen Company Details
Table 90. Amgen Business Overview
Table 91. Amgen Pharmaceutical Biomanufacturing Product
Table 92. Amgen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 93. Amgen Recent Development
Table 94. AstraZeneca Company Details
Table 95. AstraZeneca Business Overview
Table 96. AstraZeneca Pharmaceutical Biomanufacturing Product
Table 97. AstraZeneca Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 98. AstraZeneca Recent Development
Table 99. Takeda Pharmaceuticals Company Details
Table 100. Takeda Pharmaceuticals Business Overview
Table 101. Takeda Pharmaceuticals Pharmaceutical Biomanufacturing Product
Table 102. Takeda Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 103. Takeda Pharmaceuticals Recent Development
Table 104. Bristol-Myers Squib Company Details
Table 105. Bristol-Myers Squib Business Overview
Table 106. Bristol-Myers Squib Pharmaceutical Biomanufacturing Product
Table 107. Bristol-Myers Squib Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 108. Bristol-Myers Squib Recent Development
Table 109. Pfizer Company Details
Table 110. Pfizer Business Overview
Table 111. Pfizer Pharmaceutical Biomanufacturing Product
Table 112. Pfizer Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 113. Pfizer Recent Development
Table 114. Eli Lilly Company Details
Table 115. Eli Lilly Business Overview
Table 116. Eli Lilly Pharmaceutical Biomanufacturing Product
Table 117. Eli Lilly Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 118. Eli Lilly Recent Development
Table 119. Novartis Company Details
Table 120. Novartis Business Overview
Table 121. Novartis Pharmaceutical Biomanufacturing Product
Table 122. Novartis Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 123. Novartis Recent Development
Table 124. GSK Company Details
Table 125. GSK Business Overview
Table 126. GSK Pharmaceutical Biomanufacturing Product
Table 127. GSK Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 128. GSK Recent Development
Table 129. CSL Limited Company Details
Table 130. CSL Limited Business Overview
Table 131. CSL Limited Pharmaceutical Biomanufacturing Product
Table 132. CSL Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 133. CSL Limited Recent Development
Table 134. Regeneron Pharmaceuticals Company Details
Table 135. Regeneron Pharmaceuticals Business Overview
Table 136. Regeneron Pharmaceuticals Pharmaceutical Biomanufacturing Product
Table 137. Regeneron Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 138. Regeneron Pharmaceuticals Recent Development
Table 139. Gilford Company Details
Table 140. Gilford Business Overview
Table 141. Gilford Pharmaceutical Biomanufacturing Product
Table 142. Gilford Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 143. Gilford Recent Development
Table 144. Biogen Company Details
Table 145. Biogen Business Overview
Table 146. Biogen Pharmaceutical Biomanufacturing Product
Table 147. Biogen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 148. Biogen Recent Development
Table 149. GileadSciences Company Details
Table 150. GileadSciences Business Overview
Table 151. GileadSciences Pharmaceutical Biomanufacturing Product
Table 152. GileadSciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 153. GileadSciences Recent Development
Table 154. Moderna Company Details
Table 155. Moderna Business Overview
Table 156. Moderna Pharmaceutical Biomanufacturing Product
Table 157. Moderna Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 158. Moderna Recent Development
Table 159. Sarepta Therapeutics, Inc. Company Details
Table 160. Sarepta Therapeutics, Inc. Business Overview
Table 161. Sarepta Therapeutics, Inc. Pharmaceutical Biomanufacturing Product
Table 162. Sarepta Therapeutics, Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 163. Sarepta Therapeutics, Inc. Recent Development
Table 164. Changchun High-Tech Industry Company Details
Table 165. Changchun High-Tech Industry Business Overview
Table 166. Changchun High-Tech Industry Pharmaceutical Biomanufacturing Product
Table 167. Changchun High-Tech Industry Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 168. Changchun High-Tech Industry Recent Development
Table 169. Sino Biopharmaceutical Limited Company Details
Table 170. Sino Biopharmaceutical Limited Business Overview
Table 171. Sino Biopharmaceutical Limited Pharmaceutical Biomanufacturing Product
Table 172. Sino Biopharmaceutical Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 173. Sino Biopharmaceutical Limited Recent Development
Table 174. Sobi Company Details
Table 175. Sobi Business Overview
Table 176. Sobi Pharmaceutical Biomanufacturing Product
Table 177. Sobi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 178. Sobi Recent Development
Table 179. 3SBio Inc. Company Details
Table 180. 3SBio Inc. Business Overview
Table 181. 3SBio Inc. Pharmaceutical Biomanufacturing Product
Table 182. 3SBio Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 183. 3SBio Inc. Recent Development
Table 184. Beijing Tiantan Biological Company Details
Table 185. Beijing Tiantan Biological Business Overview
Table 186. Beijing Tiantan Biological Pharmaceutical Biomanufacturing Product
Table 187. Beijing Tiantan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 188. Beijing Tiantan Biological Recent Development
Table 189. Innovent Biologics Company Details
Table 190. Innovent Biologics Business Overview
Table 191. Innovent Biologics Pharmaceutical Biomanufacturing Product
Table 192. Innovent Biologics Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 193. Innovent Biologics Recent Development
Table 194. Qilu Pharmaceutical Company Details
Table 195. Qilu Pharmaceutical Business Overview
Table 196. Qilu Pharmaceutical Pharmaceutical Biomanufacturing Product
Table 197. Qilu Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 198. Qilu Pharmaceutical Recent Development
Table 199. Boehringer Ingelheim Company Details
Table 200. Boehringer Ingelheim Business Overview
Table 201. Boehringer Ingelheim Pharmaceutical Biomanufacturing Product
Table 202. Boehringer Ingelheim Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 203. Boehringer Ingelheim Recent Development
Table 204. BeiGene Company Details
Table 205. BeiGene Business Overview
Table 206. BeiGene Pharmaceutical Biomanufacturing Product
Table 207. BeiGene Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 208. BeiGene Recent Development
Table 209. Jiangsu Hengrui Pharmaceuticals Company Details
Table 210. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 211. Jiangsu Hengrui Pharmaceuticals Pharmaceutical Biomanufacturing Product
Table 212. Jiangsu Hengrui Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 213. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 214. Hualan Biological Company Details
Table 215. Hualan Biological Business Overview
Table 216. Hualan Biological Pharmaceutical Biomanufacturing Product
Table 217. Hualan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 218. Hualan Biological Recent Development
Table 219. Shanghai Henlius Biotech Company Details
Table 220. Shanghai Henlius Biotech Business Overview
Table 221. Shanghai Henlius Biotech Pharmaceutical Biomanufacturing Product
Table 222. Shanghai Henlius Biotech Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 223. Shanghai Henlius Biotech Recent Development
Table 224. Taibang Biologic Company Details
Table 225. Taibang Biologic Business Overview
Table 226. Taibang Biologic Pharmaceutical Biomanufacturing Product
Table 227. Taibang Biologic Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 228. Taibang Biologic Recent Development
Table 229. Gan & Lee Pharmaceuticals Company Details
Table 230. Gan & Lee Pharmaceuticals Business Overview
Table 231. Gan & Lee Pharmaceuticals Pharmaceutical Biomanufacturing Product
Table 232. Gan & Lee Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 233. Gan & Lee Pharmaceuticals Recent Development
Table 234. Anhui Anke Biotechnology Company Details
Table 235. Anhui Anke Biotechnology Business Overview
Table 236. Anhui Anke Biotechnology Pharmaceutical Biomanufacturing Product
Table 237. Anhui Anke Biotechnology Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 238. Anhui Anke Biotechnology Recent Development
Table 239. Tonghua Dongbao Pharmaceutical Company Details
Table 240. Tonghua Dongbao Pharmaceutical Business Overview
Table 241. Tonghua Dongbao Pharmaceutical Pharmaceutical Biomanufacturing Product
Table 242. Tonghua Dongbao Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 243. Tonghua Dongbao Pharmaceutical Recent Development
Table 244. Shanghai Junshi Biosciences Company Details
Table 245. Shanghai Junshi Biosciences Business Overview
Table 246. Shanghai Junshi Biosciences Pharmaceutical Biomanufacturing Product
Table 247. Shanghai Junshi Biosciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 248. Shanghai Junshi Biosciences Recent Development
Table 249. Sichuan Yuanda Shuyang Pharmaceutical Company Details
Table 250. Sichuan Yuanda Shuyang Pharmaceutical Business Overview
Table 251. Sichuan Yuanda Shuyang Pharmaceutical Pharmaceutical Biomanufacturing Product
Table 252. Sichuan Yuanda Shuyang Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 253. Sichuan Yuanda Shuyang Pharmaceutical Recent Development
Table 254. Kexing Biopharm Company Details
Table 255. Kexing Biopharm Business Overview
Table 256. Kexing Biopharm Pharmaceutical Biomanufacturing Product
Table 257. Kexing Biopharm Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)
Table 258. Kexing Biopharm Recent Development
Table 259. Research Programs/Design for This Report
Table 260. Key Data Information from Secondary Sources
Table 261. Key Data Information from Primary Sources
Table 262. Authors List of This Report
List of Figures
Figure 1. Pharmaceutical Biomanufacturing Picture
Figure 2. Global Pharmaceutical Biomanufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Pharmaceutical Biomanufacturing Market Share by Type: 2024 VS 2031
Figure 4. Antibody Drugs Features
Figure 5. Recombinant Protein Drugs Features
Figure 6. Blood Products Features
Figure 7. Vaccine Preparations Features
Figure 8. CAR-T Drugs Features
Figure 9. Small Nucleic Acid Drugs Features
Figure 10. Others Features
Figure 11. Global Pharmaceutical Biomanufacturing Market Size Comparison by Class (2020-2031) & (US$ Million)
Figure 12. Monoclonal Antibodies Features
Figure 13. Antibody-drug Conjugates (ADCs) Features
Figure 14. Peptide Drugs Features
Figure 15. Enzyme Replacement Therapy Features
Figure 16. Human Albumin Features
Figure 17. Immunoglobulins Features
Figure 18. Coagulation Factors Features
Figure 19. COVID-19 Vaccines Features
Figure 20. Other Vaccines Features
Figure 21. Global Pharmaceutical Biomanufacturing Market Size by Application (2020-2031) & (US$ Million)
Figure 22. Global Pharmaceutical Biomanufacturing Market Share by Application: 2024 VS 2031
Figure 23. Oncology Case Studies
Figure 24. Infectious Diseases Case Studies
Figure 25. Immune and Inflammatory Diseases Case Studies
Figure 26. Endocrine and Metabolic Diseases Case Studies
Figure 27. Neurological Diseases Case Studies
Figure 28. Hematologic Diseases Case Studies
Figure 29. Others Case Studies
Figure 30. Pharmaceutical Biomanufacturing Report Years Considered
Figure 31. Global Pharmaceutical Biomanufacturing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 32. Global Pharmaceutical Biomanufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 33. Global Pharmaceutical Biomanufacturing Market Share by Region: 2024 VS 2031
Figure 34. Global Pharmaceutical Biomanufacturing Market Share by Players in 2024
Figure 35. Global Pharmaceutical Biomanufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 36. The Top 10 and 5 Players Market Share by Pharmaceutical Biomanufacturing Revenue in 2024
Figure 37. North America Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. North America Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)
Figure 39. United States Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Canada Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Europe Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Europe Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)
Figure 43. Germany Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. France Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. U.K. Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Italy Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Russia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Ireland Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Pharmaceutical Biomanufacturing Market Share by Region (2020-2031)
Figure 51. China Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Japan Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. South Korea Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Southeast Asia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. India Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Australia & New Zealand Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Latin America Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 58. Latin America Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)
Figure 59. Mexico Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 60. Brazil Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 61. Middle East & Africa Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 62. Middle East & Africa Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)
Figure 63. Israel Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 64. Saudi Arabia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 65. UAE Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 66. Roche Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 67. Merck Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 68. Novo Nordisk Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 69. Sanofi Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 70. Johnson & Johnson Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 71. AbbVie Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 72. Amgen Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 73. AstraZeneca Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 74. Takeda Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 75. Bristol-Myers Squib Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 76. Pfizer Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 77. Eli Lilly Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 78. Novartis Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 79. GSK Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 80. CSL Limited Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 81. Regeneron Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 82. Gilford Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 83. Biogen Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 84. GileadSciences Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 85. Moderna Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 86. Sarepta Therapeutics, Inc. Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 87. Changchun High-Tech Industry Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 88. Sino Biopharmaceutical Limited Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 89. Sobi Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 90. 3SBio Inc. Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 91. Beijing Tiantan Biological Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 92. Innovent Biologics Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 93. Qilu Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 94. Boehringer Ingelheim Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 95. BeiGene Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 96. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 97. Hualan Biological Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 98. Shanghai Henlius Biotech Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 99. Taibang Biologic Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 100. Gan & Lee Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 101. Anhui Anke Biotechnology Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 102. Tonghua Dongbao Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 103. Shanghai Junshi Biosciences Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 104. Sichuan Yuanda Shuyang Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 105. Kexing Biopharm Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)
Figure 106. Bottom-up and Top-down Approaches for This Report
Figure 107. Data Triangulation
Figure 108. Key Executives Interviewed
